|
EP3689886A1
(en)
*
|
2013-01-16 |
2020-08-05 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
|
|
SG11201606239UA
(en)
|
2014-01-28 |
2016-08-30 |
Buck Inst For Res On Aging |
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
|
|
CN106456699B
(zh)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
|
|
EP3177144A4
(en)
|
2014-07-22 |
2018-01-24 |
Bioventures, LLC. |
Compositions and methods for selectively depleting senescent cells
|
|
WO2016127135A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Unity Biotechnology, Inc. |
Compounds and uses in treatment of senescence-associated conditons
|
|
US20180000816A1
(en)
*
|
2015-02-06 |
2018-01-04 |
Unity Biotechnology, Inc. |
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
|
|
WO2017101851A1
(en)
*
|
2015-12-18 |
2017-06-22 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
|
US11135198B2
(en)
|
2016-03-28 |
2021-10-05 |
Presage Biosciences, Inc. |
Pharmaceutical combinations for the treatment of cancer
|
|
EP3445452A4
(en)
|
2016-04-21 |
2019-10-30 |
BioVentures, LLC |
COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
|
|
CN106177955B
(zh)
*
|
2016-08-18 |
2018-03-16 |
广州威溶特医药科技有限公司 |
Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
|
|
WO2018098534A1
(en)
*
|
2016-12-02 |
2018-06-07 |
Garvan Institute Of Medical Research |
Methods of treating cancer and reagents thereof
|
|
AU2018314280B2
(en)
|
2017-08-11 |
2023-07-20 |
Rsem, Société En Commandite |
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
|
|
WO2019033122A1
(en)
*
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|
|
US20200354336A9
(en)
*
|
2017-08-11 |
2020-11-12 |
Unity Biotechnology, Inc. |
Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
|
|
US10588916B2
(en)
|
2017-10-31 |
2020-03-17 |
Unity Biotechnology, Inc. |
Technology to inhibit vascular changes that lead to vision loss in the eye
|
|
WO2019133988A1
(en)
|
2017-12-30 |
2019-07-04 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
USRE50643E1
(en)
|
2018-01-10 |
2025-10-21 |
Recurium Ip Holdings, Llc |
Benzamide compounds
|
|
US12118414B2
(en)
|
2018-01-22 |
2024-10-15 |
Bioventures, Llc |
BCL-2 proteins degraders for cancer treatment
|
|
KR102738032B1
(ko)
|
2018-04-29 |
2024-12-05 |
베이진 엘티디 |
Bcl-2 억제제
|
|
CA3056878C
(en)
|
2018-04-30 |
2021-03-30 |
Unity Biotechnology |
Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
US10738042B2
(en)
|
2018-04-30 |
2020-08-11 |
Unity Biotechnology, Inc. |
Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
EP3788052A4
(en)
|
2018-04-30 |
2021-05-26 |
Unity Biotechnology, Inc. |
ACYLPHOSPHONAMIDATE AND ACYLBENZYLAMINE AS ANTAGONISTS OF THE BCL FAMILY FOR THE CLINICAL MANAGEMENT OF CONDITIONS CAUSED OR MEDIATED BY SENESCENT CELLS AND TREATMENT OF CANCER
|
|
US12084423B2
(en)
|
2018-05-18 |
2024-09-10 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
US10717722B2
(en)
|
2018-06-13 |
2020-07-21 |
Unity Biotechnology, Inc. |
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
EP3829593A4
(en)
*
|
2018-07-31 |
2022-04-13 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
|
|
US11491168B2
(en)
|
2018-07-31 |
2022-11-08 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
|
|
CA3094449C
(en)
|
2018-07-31 |
2023-02-28 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
|
|
WO2020024834A1
(en)
|
2018-07-31 |
2020-02-06 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
AU2019315466B2
(en)
|
2018-07-31 |
2022-05-19 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
|
|
CN114522167A
(zh)
|
2018-07-31 |
2022-05-24 |
苏州亚盛药业有限公司 |
Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
|
|
WO2020041405A1
(en)
|
2018-08-22 |
2020-02-27 |
Newave Pharmaceutical Inc. |
Bcl-2 inhibitors
|
|
US11872237B2
(en)
*
|
2018-12-28 |
2024-01-16 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Pharmaceutical composition and preparation method thereof
|
|
EP3820878A4
(en)
*
|
2019-01-04 |
2022-04-20 |
Ascentage Pharma (Suzhou) Co., Ltd. |
METHOD FOR PREPARING SULFONAMIDE COMPOUNDS
|
|
CN111410650B
(zh)
*
|
2019-01-04 |
2020-12-08 |
苏州亚盛药业有限公司 |
制备磺胺类药物的方法
|
|
TWI770503B
(zh)
*
|
2019-05-13 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
|
|
TW202114692A
(zh)
*
|
2019-07-02 |
2021-04-16 |
大陸商蘇州亞盛藥業有限公司 |
一種含有mTOR抑制劑的藥物組合及其應用
|
|
AU2020321068A1
(en)
*
|
2019-07-31 |
2021-03-18 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
US20220372042A1
(en)
|
2019-10-03 |
2022-11-24 |
Newave Pharmaceutical Inc. |
Condensed heterocycles as bcl-2 inhibitors
|
|
CN112707900B
(zh)
*
|
2019-10-24 |
2022-06-10 |
上海科技大学 |
蛋白降解剂及其在疾病治疗中的应用
|
|
US12516053B2
(en)
|
2019-10-28 |
2026-01-06 |
Beone Medicines I Gmbh |
Bcl-2 inhibitors
|
|
TWI885019B
(zh)
|
2019-11-27 |
2025-06-01 |
大陸商蘇州亞盛藥業有限公司 |
用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
|
|
CN118542872A
(zh)
*
|
2019-12-04 |
2024-08-27 |
苏州亚盛药业有限公司 |
药物组合及其用途
|
|
WO2021119439A1
(en)
*
|
2019-12-11 |
2021-06-17 |
The Regents Of The University Of Michigan |
Compositions and methods for systemic delivery of bcl-2 and bcl-xl antagonists
|
|
CN113350281B
(zh)
*
|
2020-03-02 |
2023-08-15 |
苏州亚盛药业有限公司 |
载药聚合物胶束及其制剂和制备方法
|
|
WO2021204060A1
(en)
*
|
2020-04-10 |
2021-10-14 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combinations of bcl-2/bcl-xl inhibitors and related uses
|
|
CN116802179A
(zh)
|
2020-04-15 |
2023-09-22 |
百济神州有限公司 |
Bcl-2抑制剂
|
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
|
EP4175644A1
(en)
|
2020-07-06 |
2023-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
|
US12528832B2
(en)
|
2020-07-13 |
2026-01-20 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Crystalline or amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts
|
|
WO2022022706A1
(en)
*
|
2020-07-31 |
2022-02-03 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Compositions and methods for treating lung diseases
|
|
AU2020477113A1
(en)
*
|
2020-11-10 |
2023-06-22 |
Pharmaron Beijing Co., Ltd. |
Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same
|
|
WO2022111647A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof
|
|
WO2022120114A1
(en)
|
2020-12-04 |
2022-06-09 |
University Of Notre Dame Du Lac |
Method of encapsulating single cells utilizing an alternating current electrospray
|
|
JP2024528174A
(ja)
|
2021-08-02 |
2024-07-26 |
アセンテージ ファーマ（スーチョウ）カンパニー，リミティド |
医薬組合せおよびその使用
|
|
WO2024027706A1
(en)
*
|
2022-08-02 |
2024-02-08 |
Beijing Neox Biotech Limited |
Bcl-xl degrading compounds
|
|
TW202415647A
(zh)
*
|
2022-09-06 |
2024-04-16 |
大陸商西藏海思科製藥有限公司 |
抑制Bcl-2或Bcl-xL的化合物及其在醫藥上的應用
|
|
WO2024245312A1
(en)
*
|
2023-05-30 |
2024-12-05 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Bcl-2/bcl-xl protein degrader and use thereof
|
|
WO2025087879A2
(en)
|
2023-10-23 |
2025-05-01 |
Institut National de la Santé et de la Recherche Médicale |
Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
|